Anticoagulation in type 2 myocardial infarctions: Lessons learned from the rivaroxaban in type 2 myocardial infarctions feasibility trial

Background: Type 2 myocardial infarction (T2MI) occurs when myocardial oxygen demand exceeds myocardial oxygen supply. T2MIs occur more frequently and have worse outcomes compared to Type 1 myocardial infarction caused by an acute plaque rupture. No clinical trial evidence is available to guide phar...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Pishoy Gouda, Robert Kay, Arjun Gupta, Tiffany Yuen, Malik Elharram, Jean-Bernard Breau, Syed Gilani, Darren Lau, Janek Senaratne, Albert KY. Tsui, Ross Tsuyuki, Michelle Graham
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-06-01
Edice:	Contemporary Clinical Trials Communications
Témata:	Type 2 myocardial infarction Anticoagulation Clinical trials
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2451865423000893
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!